Vaccine Scheduler
France and Romania: Comparison of recommended vaccinations
| France | Romania | |
|---|---|---|
| General recommendation | ||
| Recommendation for specific groups only | ||
| Catch-up (e.g. if previous doses missed) | ||
| Vaccination not funded by the National Health system | ||
| Mandatory vaccination | ||
| Birth | Months | Years | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 3 | 4 | 5 | 6 | 11 | 12 | 16-18 | 2 | 5 | 6 | 11 | 13 | 14 | 15 | 17 | 18 | 19 | 24 | 25 | 35 | 45 | 65 | 74 | ≥ 75 | ||||
| Coronavirus disease (COVID-19)1 | COVID-197 | |||||||||||||||||||||||||||
| COVID-198 | ||||||||||||||||||||||||||||
| tuberculosis | BCG9 | |||||||||||||||||||||||||||
| BCG10 | ||||||||||||||||||||||||||||
| rotavirus infection | ROTA | ROTA | ROTA11 | |||||||||||||||||||||||||
| diphtheria2 | D | D | D | D | d | d12 | d | d13 | ||||||||||||||||||||
| D | D | D | D | d | ||||||||||||||||||||||||
| tetanus2 | TT | TT | TT | TT | TT | TT12 | TT | TT13 | ||||||||||||||||||||
| TT | TT | TT | TT | TT | ||||||||||||||||||||||||
| pertussis | acP14 | acP | acP | acP | acp | acp15 | ||||||||||||||||||||||
| acP | acP | acP | acP | acp | acp16 | |||||||||||||||||||||||
| poliomyelitis | IPV | IPV | IPV | IPV | IPV | IPV12 | IPV | IPV13 | ||||||||||||||||||||
| IPV | IPV | IPV | IPV | |||||||||||||||||||||||||
| Haemophilus influenzae type b infection | Hib | Hib | Hib | |||||||||||||||||||||||||
| Hib | Hib | Hib | ||||||||||||||||||||||||||
| hepatitis B | HepB17 | HepB | HepB | HepB | HepB18 | |||||||||||||||||||||||
| HepB19 | HepB | HepB | HepB | |||||||||||||||||||||||||
| pneumococcal disease3 | PCV13 | PCV13 | PCV13 | PCV2020 | ||||||||||||||||||||||||
| PCV | PCV | PCV | ||||||||||||||||||||||||||
| meningococcal disease4 | MenB21 | MenB - MenC22 | MenB - MenC23 | MenC24 | ||||||||||||||||||||||||
| measles5 | MEAS25 | MEAS | MEAS | MEAS26 | MEAS27 | |||||||||||||||||||||||
| MEAS | MEAS | |||||||||||||||||||||||||||
| mumps5 | MUMPS | MUMPS | MUMPS26 | MUMPS27 | ||||||||||||||||||||||||
| MUMPS | MUMPS | |||||||||||||||||||||||||||
| rubella5 | RUBE | RUBE | RUBE26 | RUBE28 | ||||||||||||||||||||||||
| RUBE | RUBE | |||||||||||||||||||||||||||
| human papillomavirus infection | HPV (F/M)29 | HPV (F/M)30 | ||||||||||||||||||||||||||
| HPV (F)31 | ||||||||||||||||||||||||||||
| influenza6 | LAIV | IIV4 | ||||||||||||||||||||||||||
| IIV3 | ||||||||||||||||||||||||||||
| herpes zoster | ZOS32 | |||||||||||||||||||||||||||
Footnotes:
- https://www.has-sante.fr/jcms/p_3197104/fr/strategie-vaccinale-contre-le-sars-cov-2
- Risk group vaccination of dT for pregnant women
- August 2023: Updated recommendations for pneumococcal vaccination published including policies on continued vaccination for those previously vaccinated with PCV13 and/or PPSV23 see https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte
- MenB/MenC/MenACYW vaccination: Recommendations for specific at-risk groups apply - refer to the national immunisation policy document for further information (link provided below)
- contacts from outbreaks of measles, mumps, rubella and flue, regardless of age
- For risk groups established by the World Health Organization
- https://www.has-sante.fr/jcms/p_3178533/fr/vaccination-dans-le-cadre-de-la-covid-19
- https://vaccinare-covid.gov.ro/
- Only recommended for children at high-risk of tuberculosis. Please refer to original document for detailled information on risk-groups.
- Administration during the 2-7 days after delivery
- 3rd dose only for pentavalent rotavirus vaccines
- dTacp-IPV or dTT-IPV if last dTacp-IPV received in the previous 5 years
- dTT-IPV every 10 years from 65 years of age
- or 8 weeks of age
- For those who did not receive a dose of pertussis containing vaccine during the past 5 years, a booster with a quadrivalent vaccine (dTacp-IPV) is recommended at the time of the Td-IPV booster at 25 years. For those aged 25 years and above that did not receive a booster dose, catch-up with a dTacp-IPV vaccine can be proposed until 39 years of age. Recommendation to have an interval of 10 years in adults between a documented pertussis and pertussis re-vaccination. Vaccination offered to pregnant women from 2nd trimester and preferably between 20 and 36 weeks of pregnancy. More information available at: calendrier_vaccinal_maj-juin23.pdf (sante.gouv.fr)
- Vaccination during pregnancy
- Babies born to a mother infected with hepatitis B will be offered a first dose at birth simultaneously with HB immunoglobulin, one month of age and 6 month of age. Four doses scheme (0-1-2-6 months) for premature <32 weeks or less than 2 kg. This intervention shall be evaluated at 9 month of age through HBs Ag and anti-HBs antibodies testing, preferably one to four month after the last vaccine dose.
- Three doses in a 0, 1, 6 month schedule. From 11 to 15 years, 2 doses in a 0, 6 schedule
- Within 24 hours after birth. In the event that the vaccine against Hepatitis B is not available, a different schedule applies for babies born of HBsAG positive mothers. More information available at: http://www.cnscbt.ro/index.php/calendarul-national-de-vaccinare
- From August 2023, PCV20 recommended instead of a mixed schedule PCV13+PPSV23 in adults from 18 years of age for individuals at risk. see https://www.has-sante.fr/jcms/p_3457419/fr/strategie-de-vaccination-contre-les-infections-a-pneumocoque-place-du-vaccin-pneumococcique-polyosidique-conjugue-20-valent-adsorbe-chez-l-adulte for more information
- Vaccination introduced in 2022.
- Men B introduced in 2022. Not mandatory.
- Men B is not mandatory.
- 1 dose until 24 years
- Update 28 June 2013:For a full description of recommendations, please refer to: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=362. The vaccination from 9 months of age of children entering day care was suspended. Updated recommendations - Measles vaccination for infants under 12 months of age - travelling to countries of high measles endemicity or countries with no measles elimination programmes or in case of exposure to measles cases - One dose of monovalent measles vaccines for infants aged 6 to 8 months. Thereafter 2 doses of MMR as per national recommendations. - Trivalent vaccine can be used for infants aged 9 to 11 months. Thereafter 1 dose of MMR between 12 and 15 month. of MMR are recommended as per national recommendations. In case of exposure to measles cases, administration should occur within 72 hours after exposure to the index case.
- 2 doses of MMR one month appart if no previous vaccination ; 1 dose if only one dose previously
- Two MMR doses in total among individuals born from 1980
- Two MMR doses in total among individuals born from 1980. For rubella, one dose of MMR among unvaccinated woman.
- The extension of HPV vaccination to boys aged 11 to 14 with catch-up vaccination for those aged between 15 and 19. This recommendation is applicable since January 1, 2021.
- Girls and boy catch-up vaccination recommended. Three-dose schedule at 0, 1-2 and 6 months
- Girls-only vaccination recommended. Two-dose schedule administered 6 month apart. 9-valent.
- for further information, please consult: http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=389